Royal Surrey NHS Foundation Trust
Guildford, Surrey, GU27XX, United Kingdom
Location status: Recruiting
Location contact
Ben Creagh-Brown, BM, PhD
CONTACT
Charlie Piercy, MSc
CONTACT
Charlie Piercy, MSc
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06613256
The goal of this observational study is to characterise changes in gene expression in endothelial cells in patients with either sepsis or post major abdominal surgery.
The main question we plan to answer is: 'What molecular pathways are differentially expressed during inflammatory pathologies?'
Interested in participating?
Request Info18 year and older
All sexes
Observational
Guildford, Surrey, GU27XX, United Kingdom
Location status: Recruiting
Ben Creagh-Brown, BM, PhD
CONTACT
Charlie Piercy, MSc
CONTACT
Charlie Piercy, MSc
PRINCIPAL_INVESTIGATOR
The immune system is a complex network of cells and molecules that protects the body from infection and injury. When the immune system is activated, it produces inflammation, which is a natural response to help heal the body. However, too much inflammation can be harmful and lead to serious complications, such as sepsis, low blood pressure, organ failure and death.
The interaction of cells that line the blood vessels (endothelial cells, EC) with the immune system, is believed to be the root cause of these symptoms. When exposed to inflammation, the instructional molecules (RNA) inside the EC change. This leads to a change of operation promoting the severe symptoms previously mentioned.
Researchers have developed new safe techniques to collect these cells from the blood vessels of patients to study disorders like diabetes, heart disease and stroke. This technique involves gently inserting a metal guidewire into an arm vein to collect ECs.
This study plans to collect ECs from patients undergoing surgery or admitted to intensive care. We also plan to collect control samples from healthy volunteers. Samples will be collected over the duration of the patients to RSFT. The RNA will be removed from the cells and counted to highlight changes in instructions in the cells.
Data from this study will potentially highlight new pathways involved in inflammation and help classify how some patients will react to current treatments. To obtain this data, this study will be split into 2 parts. Part 1 focuses on collecting one sample from a patient when they are at their most unwell states and comparing that to a sample from a healthy person. Part 2 will focus on key mRNA molecules identified during Part 1 and identifying how their expression changes over time.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Healthy volunteer
Surgical patients
Critically ill patients
Exclusion criteria
Healthy volunteer
Surgical patients
Critically ill patients
Endothelial cell sample collected from the antecubital fossa of patients. A vein in the antecubital fossa is cannulated with a 20 g valveless cannula. A metal guidewire is then passed into the vessel to collect endothelial cells for analysis
Time frame: 2 years
Using RNA extracted from the two patient cohorts and controls in part 1, we plan to use RNA-SEQ to identify differentially expressed genes. Once we have identified genes we believe to be critically involved with endothelial dysfunction, we will then perform serial sampling on an additional two groups of patients and using qRT-PCR to analyse gene expression changes.
Contact information is provided by the study sponsor or research team.
Ben Creagh-Brown, BM, PhD
CONTACT
Charlie Piercy, MSc
CONTACT
Royal Surrey County Hospital NHS Foundation Trust
Other
Acronym: JEDI-2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07658014
Cardiovascular Diseases, Infections
Querétaro City, Querétaro, Mexico
View Trial DetailsNCT05146336
Acute Liver Failure, Acute Respiratory Distress Syndrome
Klagenfurt, Austria
View Trial DetailsNCT03333278
Cardiovascular Diseases, Critical Illness
Clayton, Victoria, Australia
View Trial DetailsNCT07215702
Acute Kidney Injury, Female Urogenital Diseases
Tucson, Arizona, United States
View Trial Details